Variable Interval Versus Set Interval Aflibercept for DME
Part of paid clinical trials in Bakersfield, California.
- Sponsor
- California Retina Consultants
- Study ID
- NCT02392364
- Phase
- PHASE4
- Status
- Completed
Conditions
- Cystoid Macular Edema
- Diabetic Macular Edema
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
Study Details
The purpose of this study is to compare the safety and efficacy of intravitreal Eylea injections at a set interval, versus a variable dosing schedule (likely longer than one month), based on a specific individual's disease progression. There will be approximately 50 men and women at least 18 years of age, diagnosed with type 1 or type 2 diabetes, taking part in this study at 5 locations in the United States.
Key Dates
- Start date
- Apr 15, 2015
- Status verified
- Jan 2019
- Primary completion
- Nov 15, 2018
- Completion
- Nov 15, 2018
Study Design
- Enrollment
- 50 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Active Comparator: Variable Treatment Dosing ArmGroup 1 will receive injections every 4 weeks until diabetic macular edema on the OCT is decreased and stable. At that point, the length of time between injections may increase, depending on how the study eye is doing. The interval between study eye treatments may maintain, increase, or decrease once the variable treatment dosing has begun. This will be determined by an algorithm designed into a computer program
- Active Comparator: Monthly Treatment ArmGroup 2 will receive 5 intravitreal injections, monthly, for the first 5 months of the study. After those initial injections, visits/treatment will be every 8 weeks.
Primary Outcome Measure
BCVA Change [ Time Frame: Week 0 to Week 52 ]
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| California Retina Consultants - Bakersfield | Bakersfield | California | 93039 | - |
| California Retina Consultants - Santa Barbara Office | Santa Barbara | California | 93103 | - |
Find similar trials in Bakersfield, CA
By condition
By specialty
Related Studies
- A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)PHASE1 · Recruiting · Genentech, Inc. · Peoria, Arizona
- CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DMEPHASE3 · Recruiting · EyePoint Pharmaceuticals, Inc. · Gilbert, Arizona
- COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DMEPHASE3 · Recruiting · EyePoint Pharmaceuticals, Inc. · Bakersfield, California
- A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are ToleratedPHASE1/PHASE2 · Recruiting · Boehringer Ingelheim · Phoenix, Arizona